The cancer immunotherapy has brought new ray of hope in cancer patients with its capability of curing cancer with less side effects. However not all patients responds to therapy. In this study we have employed Nuclear Magnetic Spectroscopy (NMR) and in vivo hyperpolarized 1-13C pyruvate magnetic resonance spectroscopy (MRS) to differentiate immunotherapy responding from immunotherapy resisting melanoma.
This abstract and the presentation materials are available to members only; a login is required.